UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which each class is registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01. | Other Events. |
As previously reported, on August 6, 2026, TCGX Acquisition Corp., a Cayman Islands exempted company (the “Company”), consummated its initial public offering (the “Offering”) of 8,625,000 Class A ordinary shares of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), including 1,125,000 Class A Ordinary Shares issued pursuant to the full exercise by the underwriters of their over-allotment option in connection with the closing of the IPO. The Class A Ordinary Shares were sold at an offering price of $10.00 per share, generating gross proceeds to the Company of $86,250,000.
As previously reported, on August 6, 2026, simultaneously with the consummation of the Offering, the Company consummated the private placement of an aggregate of 522,500 Class A Ordinary Shares (the “Private Placement Shares”) at a price of $10.00 per Private Placement Share, generating gross proceeds of $5,225,000. Of the 522,500 Private Placement Shares, TCGX Sponsor, LLC (the “Sponsor”) purchased 436,250 Private Placement Shares and Jefferies LLC purchased 86,250 Private Placement Shares.
A total of $86,250,000 ($10.00 per Class A Ordinary Share) of the net proceeds from the Offering and the Private Placement, which amount excludes $862,500 of the underwriter’s discount, was placed in a trust account established for the benefit of the Company’s public shareholders, with Odyssey Transfer and Trust Company acting as trustee.
An audited balance sheet as of August 6, 2026, reflecting receipt of the proceeds from the Offering and the Private Placement, has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are being filed herewith:
| Exhibit |
Description | |
| 99.1 | Audited Balance Sheet, as of August 6, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TCGX ACQUISITION CORP. | ||||||
| Date: August 12, 2026 | By: | /s/ Chen Yu | ||||
| Name: | Chen Yu, M.D., M.B.A. | |||||
| Title: | Chief Executive Officer | |||||
2